MX376241B - Uso de anticuerpos anti-il-1a en el tratamiento de enfermedades vasculares y sus complicaciones. - Google Patents

Uso de anticuerpos anti-il-1a en el tratamiento de enfermedades vasculares y sus complicaciones.

Info

Publication number
MX376241B
MX376241B MX2015004286A MX2015004286A MX376241B MX 376241 B MX376241 B MX 376241B MX 2015004286 A MX2015004286 A MX 2015004286A MX 2015004286 A MX2015004286 A MX 2015004286A MX 376241 B MX376241 B MX 376241B
Authority
MX
Mexico
Prior art keywords
complications
vascular disease
treating vascular
chance
expected
Prior art date
Application number
MX2015004286A
Other languages
English (en)
Spanish (es)
Other versions
MX2015004286A (es
Inventor
John Simard
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Publication of MX2015004286A publication Critical patent/MX2015004286A/es
Publication of MX376241B publication Critical patent/MX376241B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2015004286A 2012-10-04 2013-10-01 Uso de anticuerpos anti-il-1a en el tratamiento de enfermedades vasculares y sus complicaciones. MX376241B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261709754P 2012-10-04 2012-10-04
PCT/US2013/062903 WO2014055544A1 (en) 2012-10-04 2013-10-01 Treating vascular disease and complications thereof

Publications (2)

Publication Number Publication Date
MX2015004286A MX2015004286A (es) 2015-08-06
MX376241B true MX376241B (es) 2025-03-06

Family

ID=50432830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015004286A MX376241B (es) 2012-10-04 2013-10-01 Uso de anticuerpos anti-il-1a en el tratamiento de enfermedades vasculares y sus complicaciones.

Country Status (12)

Country Link
US (3) US20140099321A1 (enExample)
EP (3) EP2904010A4 (enExample)
JP (1) JP6460993B2 (enExample)
KR (2) KR102429919B1 (enExample)
CN (2) CN104684929A (enExample)
AU (1) AU2013327501B2 (enExample)
CA (1) CA2886747C (enExample)
HK (1) HK1211960A1 (enExample)
IL (1) IL237765B (enExample)
MX (1) MX376241B (enExample)
RU (1) RU2671955C2 (enExample)
WO (1) WO2014055544A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102946904A (zh) 2010-06-18 2013-02-27 埃克斯生物科技公司 关节炎治疗
PH12013500316A1 (en) 2010-08-23 2016-09-02 Janssen Biotech Inc Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
PT2750709T (pt) 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
JP7145162B2 (ja) 2017-02-16 2022-09-30 ヤンセン バイオテク,インコーポレイテッド 化膿性汗腺炎の処置
AU2020267329B2 (en) * 2019-05-03 2026-03-26 University Of Zurich Treatment of brain ischemia-reperfusion injury
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
KR102652849B1 (ko) 2022-03-14 2024-04-01 한국화학연구원 극성 아라미드 나노섬유로 제조한 하이드로겔

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
RU2235541C2 (ru) * 1994-10-04 2004-09-10 Эмори Юниверсити Лечение атеросклероза и других сердечно-сосудистых и воспалительных заболеваний
WO2000071753A2 (en) * 1999-05-24 2000-11-30 Interleukin Genetics, Inc. Diagnostics and therapeutics for restenosis
EP1471931A4 (en) * 2001-08-24 2006-06-14 Maine Medical Ct Res Inst NON-TRADITIONAL EXPORT OF COPPER-DEPENDENT PRO-INFLAMMATORY CYTOKINES AND METHODS, COMPOSITIONS, AND KITS THEREOF
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
HUE029003T2 (en) * 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
SG2014014534A (en) * 2009-05-29 2014-07-30 Xoma Technology Ltd CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF
JP5812669B2 (ja) 2011-04-27 2015-11-17 キヤノン株式会社 画像処理装置および画像処理方法およびコンピュータプログラム。

Also Published As

Publication number Publication date
AU2013327501B2 (en) 2018-08-09
CN113018431A (zh) 2021-06-25
EP2904010A1 (en) 2015-08-12
AU2013327501A1 (en) 2015-04-02
WO2014055544A1 (en) 2014-04-10
EP3524621A1 (en) 2019-08-14
MX2015004286A (es) 2015-08-06
CA2886747C (en) 2023-12-05
US20180057585A1 (en) 2018-03-01
JP2015531397A (ja) 2015-11-02
EP4628162A3 (en) 2025-12-03
KR20150063076A (ko) 2015-06-08
JP6460993B2 (ja) 2019-01-30
KR102296017B1 (ko) 2021-09-01
US20210403548A1 (en) 2021-12-30
IL237765B (en) 2019-06-30
US20140099321A1 (en) 2014-04-10
CA2886747A1 (en) 2014-04-10
EP2904010A4 (en) 2016-06-01
EP4628162A2 (en) 2025-10-08
RU2671955C2 (ru) 2018-11-08
CN104684929A (zh) 2015-06-03
KR102429919B1 (ko) 2022-08-05
IL237765A0 (en) 2015-05-31
RU2015110635A (ru) 2016-11-27
HK1211960A1 (en) 2016-06-03
KR20210108496A (ko) 2021-09-02

Similar Documents

Publication Publication Date Title
EP4628162A3 (en) Treating vascular disease and complications thereof
NZ595331A (en) Ex-vivo treatment of immunological disorders with pkc-theta inhibitors
ZA201700196B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
JP2015531397A5 (enExample)
NZ602219A (en) Methods and compositions for treating degos’ disease
JOP20140344B1 (ar) تركيبات وطرق لتقليل المضاعفات السلبية العظمي للقلب والاوعية الدموية
MX380273B (es) Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp.
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
AR097178A1 (es) Diagnóstico y terapias anticáncer que comprenden células madre cancerosas
LT2013018A (lt) Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus
WO2015067755A3 (en) Novel methods and antibodies for treating coagulapathy
MX2010006650A (es) Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica.
EP2670435A1 (en) Use of anti-dkk1 monoclonal antibody for treatment of liver cancer
UY33533A (es) siRNA DIRIGIDO AL VEGFA Y A MÉTODOS DE TRATAMIENTO IN VIVO
EP4279128A3 (en) Novel antibody binding to tfpi and composition comprising the same
PH12014500967A1 (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
GEP201706716B (en) Optimised subcutaneous therapeutic agents
MX356808B (es) Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia.
MX2014005895A (es) Medicamento para tratamiento terapeutico y/o mejoramiento de sepsis.
WO2012106497A3 (en) Selection and treatment of subjects
WO2013078376A3 (en) Isoxazole treatments for diabetes
HK1213921A1 (zh) 用於減少在植入支架後的糖尿病患者的主要不良心血管事件(mace)的雙重可變結構域(dvd)免疫球蛋白
Shen et al. Inguinal hernia repair with acellular tissue matrix patch for pediatric patients aged 6 to 18 years
Liu et al. Preventive effects of modified chitosan medical anti-adhesion membrane on postoperative intra-abdominal adhesion
张承磊 The treatment strategy of special distal landing zones in endovascular repair of abdominal aortic aneurysm

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: JANSSEN BIOTECH, INC.